Integral Health Asset Management LLC Has $48.63 Million Stake in Vera Therapeutics, Inc. (NASDAQ:VERA)

Integral Health Asset Management LLC increased its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 130.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,150,000 shares of the company’s stock after buying an additional 650,000 shares during the quarter. Vera Therapeutics comprises approximately 4.1% of Integral Health Asset Management LLC’s holdings, making the stock its 4th largest position. Integral Health Asset Management LLC’s holdings in Vera Therapeutics were worth $48,634,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Huntington National Bank bought a new position in Vera Therapeutics during the 4th quarter worth $26,000. Summit Investment Advisors Inc. grew its stake in Vera Therapeutics by 16.0% during the 4th quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company’s stock worth $196,000 after buying an additional 639 shares during the last quarter. AlphaQuest LLC bought a new position in shares of Vera Therapeutics in the fourth quarter worth $34,000. Alliancebernstein L.P. grew its stake in shares of Vera Therapeutics by 2.0% in the fourth quarter. Alliancebernstein L.P. now owns 40,350 shares of the company’s stock worth $1,706,000 after purchasing an additional 800 shares in the last quarter. Finally, E Fund Management Co. Ltd. grew its stake in shares of Vera Therapeutics by 22.3% in the fourth quarter. E Fund Management Co. Ltd. now owns 6,203 shares of the company’s stock worth $262,000 after purchasing an additional 1,130 shares in the last quarter. 99.21% of the stock is currently owned by institutional investors.

Vera Therapeutics Stock Down 1.2%

NASDAQ:VERA opened at $21.77 on Monday. Vera Therapeutics, Inc. has a 1 year low of $18.53 and a 1 year high of $51.61. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17. The stock has a market cap of $1.39 billion, a price-to-earnings ratio of -8.34 and a beta of 1.28. The stock has a 50-day moving average price of $24.22 and a two-hundred day moving average price of $34.65.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). During the same quarter in the prior year, the company posted ($0.56) earnings per share. As a group, equities analysts expect that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on VERA shares. Cantor Fitzgerald decreased their price target on Vera Therapeutics from $107.00 to $100.00 and set an “overweight” rating for the company in a research note on Wednesday, May 7th. Wolfe Research started coverage on Vera Therapeutics in a research note on Tuesday, February 4th. They issued an “outperform” rating and a $49.00 price target for the company. Wedbush decreased their price target on Vera Therapeutics from $34.00 to $26.00 and set a “neutral” rating for the company in a research note on Wednesday, May 7th. Guggenheim increased their price target on Vera Therapeutics from $59.00 to $61.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. Finally, JPMorgan Chase & Co. decreased their target price on Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating for the company in a research note on Tuesday, March 4th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $63.33.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.